Page 475 - 73_04

VOL. 73 (4), 1265-1285, 2007 INDIVIDUALIZACIÓN DE CARBOPLATINO EN...

(32) JOHNSON, D.H. (2004) Gefitinib in combination with gemcitabine and cispla-
tin in advanced non-small cell cancer: a phase III trial—INTACT 1. J. Clin.
(33) Oncol. 22: 777-784.
HERBST, R.S.; GIACCONE, G.; SCHILLER, J.H.; NATALE, R.B.; MILLER, V.; MANEGOLD,
(34) C.; SCAGLIOTTI, G.; ROSELL, R.; OLIFF, I.; REEVES, J.A.; WOLF, M.K.; KREBS, A.D.;
(35) AVERBUCH, S.D.; OCHS, J.S.; GROUS, J.; FANDI, A. Y JOHNSON, D.H. (2004) Gefiti-
(36) nib in combination with paclitaxel and carboplatin in advanced non-small
(37) cell lung cancer: a phase II trial—INTACT 2. J. Clin. Oncol. 22: 785-794.
(38) ROSELL, R.; DANIEL, C. Y RAMLAU, R. (2004) Randomized phase II study of
(39) cetuximab with cisplatin (C) and vinorelbine (V) vs CV alone in the first-line
(40) treatment of patients (pts) with epidermal growth factor receptor (EGFR)-
(41) expressing advanced non-small cell lung cancer (NSCLC). Program and abs-
(42) tracts of the 40th Annual Meeting of the American Society of Clinical Onco-
logy; June 5-8; New Orleans, Louisiana. Abstract 7012.
SANDLER, A.; GRAY, R.; PERRY, M.C. PERRY, M.C.; BRAHMER, J.; SCHILLER, J.H.;
DOWLATI, A.; LILENBAUM, R. Y JOHNSON, D.H. (2006) Paclitaxel–carboplatin alo-
ne or with bevacizumab for non–small-cell lung cancer. N. Engl. J. Med. 355:
2542-2550.
JEROME, E. Y GROOPMAN, L. M. I. (1999) Chemotherapy-Induced Anemia in
Adults: Incidence and Treatment. J. Natl. Cancer Inst. 91: 1616-1634.
GRACIA, S.; MONTAÑES, R.; BOVER, J.; CASES, A.; DEULOFEU, R.; DE FRANCISCO, A.
Y ORTE L. (2006) Recomendaciones sobre la utilización de ecuaciones para la
estimación del filtrado glomerular en adultos. Química Clínica 25 (5): 423-
430.
EKHART, C.; DE JORGE, M.E.; HUITEMA, A.D.R. Y SCHELLENS J.H.M. (2006) Flat
dosing of carboplatin is justified in adult patients with normal renal func-
tion. Clin. Cancer. Res. 12 (21): 6502-6508.
WRIGHT, J.G.; BODDY, A.V.; HIGHLEY, M.; FENWICK,J.; MCGILL, A. Y CALVERT, A.H.
(2001) Estimation of glomerular filtration rate in cancer patients. Br. J.
Cancer. 84: 452-459.
CHATELUT, E.; CANAL, P.; BRUNNER, V.; CHEVREAU, C.; PUJOL, A.; BONEU, A.; ROCHÉ,
H.; HOUIN, G. Y BUGAT, R. (1995) Prediction of carboplatin clearance from
standard morphological and biological patient characteristics. J. Natl. Cancer
Inst. 87(8): 573-580.
EGORIN, M.J.; REYNO, L.M.; CANETTA, R.M.; JODRELL, D.I.; SWENERTON, K.D.;
PATER, J.L.; BURROUGHS, J.N.; NOVAK, M.J. Y SRIDHARA, R. (1994) Modeling toxi-
city and response in carboplatin-based combination chemotherapy. Semin.
Oncol. 21(5 Suppl 12): 7-19.
LINDSTROM, M.J. Y BATES, T.M. (1990) Nonlinear mixed effects models for
repeated measures. Biometrics. 46: 673-687.
SHEN, M.; SCHILDER, R.J.; OBASAJU, C. Y GALLO, J.M. (2002) Population pharma-
cokinetic and limited sampling models for carboplatin administered in high-
dose combination regimens with peripheral blood stem cell support. Cancer

Chemoter. Pharmacol. 50: 243-250.

1285